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Hereditary cancers derive from gene defects that often
compromise DNA repair. Thus, BRCA-associated cancers
are sensitive to DNA-damaging agents such as cisplatin.
The efficacy of cisplatin is limited, however, by the de-
velopment of resistance. One cisplatin resistance mecha-
nism is restoration of homologous recombination (HR),
which can result from BRCA reversion mutations. How-
ever, in BRCA2 mutant cancers, cisplatin resistance can
occur independently of restored HR by a mechanism that
remains unknown. Here we performed a genome-wide
shRNA screen and found that loss of the nucleosome
remodeling factor CHD4 confers cisplatin resistance. Res-
toration of cisplatin resistance is independent of HR but
correlates with restored cell cycle progression, reduced
chromosomal aberrations, and enhanced DNA damage
tolerance. Suggesting clinical relevance, cisplatin-resistant
clones lacking genetic reversion of BRCA2 show de novo
loss ofCHD4 expression in vitro.Moreover,BRCA2mutant
ovarian cancers with reduced CHD4 expression signifi-
cantly correlate with shorter progression-free survival and
shorter overall survival. Collectively, our findings indicate
that CHD4 modulates therapeutic response in BRCA2
mutant cancer cells.
Supplemental material is available for this article.
Received November 20, 2014; revised version accepted
February 9, 2015.
BRCA1/2 mutant hereditary breast and ovarian cancers
as well as Fanconi anemia (FA) derive from common
genetic defects that compromise DNA repair by homol-
ogous recombination (HR). Thus, FA patient cells and
BRCA-associated tumors are sensitive to DNA-damaging
agents that require HR for repair processing, such as DNA
breaks induced by the DNA cross-linking agent cisplatin.
Loss of HR in BRCA1 and BRCA2 mutant cancer cells
also elicits synthetic lethality with PARP1 inhibitors. As
such, cisplatin and PARP1 inhibitors alone or in combi-
nation are actively being tested on a diverse set of tumors
with suspected BRCA- or HR-associated pathway muta-
tions (Lord et al. 2015).
The efficacy of these therapies is limited, however, by
the development of resistance. Currently, the most well-
described mechanism known to underlie resistance in
BRCA cancers is re-established DNA repair. In both
BRCA1 and BRCA2mutant cancer cells, genetic rewiring
events, including secondary or reversion mutations, can
reinstate functional gene products and HR-based DNA
repair (Edwards et al. 2008; Sakai et al. 2008, 2009). In
BRCA1 mutant cells, HR can also be restored through
loss of the DNA repair protein 53BP1, which restores
DNA end resection required for HR (Bunting et al. 2010).
Triple-negative breast cancers that express low levels of
BRCA1 and 53BP1 significantly correlate with shorter
progression-free survival (PFS) and shorter overall sur-
vival (OS) (Bouwman et al. 2010). In BRCA2 mutant
cancer cells, 53BP1 depletion does not promote therapeu-
tic resistance or improve HR. Aside from genetic re-
version, which occurs in about half of BRCA2 mutant
ovarian cancers (Norquist et al. 2011), the mechanisms
that mediate resistance to therapy in the remaining half
is unknown.
Results and Discussion
To identify factors that mediate resistance to cisplatin
chemotherapy, we performed a survival-based, loss-of-
function RNAi screen in the cisplatin-sensitive PEO1
ovarian cancer cell line. PEO1 cells carry a hemizygous
nonsense mutation (5193C>G) that generates an N-ter-
minal-truncated form of BRCA2, which cannot carry out
HR (Fig. 1A; Sakai et al. 2009). Previous selection for
cisplatin-resistant clones revealed BRCA2 reversion mu-
tations that restore HR, as in the C4-2 clone (Fig. 1A–C),
as well as clones that were resistant by an unknown
mechanism (Sakai et al. 2009). Thus, the screen was
performed in PEO1 cells because they reflect BRCA2
mutant ovarian cancers that develop both reversion and
reversion-independent mechanisms of cisplatin resis-
tance (Norquist et al. 2011).
Cells were infected with viral pools containing the
pGIPZ library comprised of ;81,000 shRNAs directed
against 28,000 unique targets or a nonsilencing control
(NSC), selected with puromycin, cisplatin-treated, and
analyzed for colony formation (see the Materials and
Methods) (Fig. 1D). Of the ;89 gene targets identified in
the initial screen (Supplemental Table S1), we elected to
focus on CHD4, a member of the nucleosome remodeling
(NuRD) complex (Denslow and Wade 2007; Ramirez and
Hagman 2009), for several reasons. Two unique unrelated
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shRNAs targeting CHD4 were identified in the RNAi
screen, and CHD4 was recently implicated as a tumor
suppressor in several female malignancies (Le Gallo et al.
2012; Zhao et al. 2013). Moreover, PEO1 cells expressing
any of four unrelated CHD4 shRNAs displayed substan-
tially increased colony survival following cisplatin treat-
ment, similar to the BRCA2 revertant line C4-2 (Fig. 1E–
G; Supplemental Fig. S1A,B). Ectopic expression of CHD4
in cells containing an shRNA targeting the 39 untrans-
lated region (UTR) of CHD4 significantly restored
cisplatin sensitivity, ruling out off-target effects (Supple-
mental Fig. S1C,D). In contrast, depletion of two other
NuRD subunits, MBD2 and CHD3, had no effect on
colony survival after treatment with cisplatin (Supple-
mental Fig. S1E–H). Furthermore, in two other cell lines
that contain a truncated BRCA2 mutant (the FA
EUFA423 cell line FA-D1 and the pancreatic cancer cell
line CAPAN-1) (Howlett et al. 2002; Edwards et al. 2008),
CHD4 depletion also increased colony survival following
cisplatin treatment (Fig. 1H–K). In addition, CHD4 de-
pletion had little effect on untreated cells but alleviated
cisplatin-induced cell cycle progression defects such that
the CHD4-depleted cells more closely resembled the
revertant cell lines (Fig. 2A; Supplemental Fig. S2A,B).
Finally, CHD4 has been shown to contribute to the DNA
damage response (for reviews, see O’Shaughnessy and
Hendrich 2013; Stanley et al. 2013).
CHD4 loss enhances sensitivity to DNA-damaging
agents (Larsen et al. 2010; Smeenk et al. 2010; Sims and
Wade 2011; Pan et al. 2012). Thus, we considered that our
findings were unique to the cisplatin response and/or
BRCA2mutant cells. Following depletion of CHD4, C4-2
cells, which have functional BRCA2, were sensitive to
cisplatin (Fig. 1L,M), the PARP inhibitor Olaparib, the
double-strand break-inducing agent zeocin, and the DNA
polymerase inhibitor aphidicolin (Supplemental Fig.
S3A–C). Moreover, in the absence of exogenous DNA-
damaging agents, C4-2 cells displayed a significant in-
duction of g-H2AX and cleaved Caspase3 along with
reduced colony-forming efficiency and growth upon de-
pletion of CHD4 or the NuRD subunit MBD2 (Supple-
mental Fig. S4A,C,F–I). In contrast, CHD4 depletion in
BRCA2 mutant PEO1 cells enhanced survival against
these DNA-damaging agents (Supplemental Fig. S3D–F).
In untreated PEO1 cells, g-H2AX and cleaved Caspase3
were not induced, and colony-forming efficiency was not
Figure 2. CHD4 depletion corrects cisplatin-induced cell cycle
progression defects and chromosomal aberrations in PEO1 cells.
(A) Cells were left untreated or cisplatin-treated and analyzed for cell
cycle with propidium iodide. (B,C) Cells were treated with cisplatin
(B), and metaphase spreads were analyzed for percentage of radials
per metaphase spread (C). At least 75 metaphase spreads were
analyzed for each variable (25 per variable in triplicate). Where
shown, error bars represent the standard deviation of the mean of
three independent experiments. Asterisks denote significance from
Student’s two-tailed, unpaired t-test: (***) P # 0.005.
Figure 1. Genome-wide screen identifies CHD4 as a mediator of
cisplatin response in BRCA2 mutant cells. (A) Schematic of BRCA2
species found in BRCA2 revertant C4-2 cells or PEO1 cells. (B)
Nuclear extracts were analyzed by immunoblot with the indicated
antibodies. Truncated BRCA2 in PEO1 cells migrates (;220 kDa),
while the revertant BRCA2 protein in C4-2 cells migrates (;390
kDa). (C) Cells were left untreated or treated with cisplatin and
analyzed for colony survival. (D) Schematic of viral infection with
shRNA pools and screening conditions. (E) Colony survival of PEO1
cells containing four unique shRNA vectors targeting CHD4 or NSC
as compared with BRCA2 revertant C4-2 cells (SF50 [in micromolar]:
PEO1+shNSC, 0.21; shCHD4 (1–4), 0.55–0.56; and C4-2+shNSC,
0.7). PEO1 cells (F,G), FA-D1 cells (H,I), CAPAN1 cells (J,K), and
BRCA2 revertant C4-2 cells (L,M) containing two unique pGIPZ
shRNA vectors (one or two) targeting CHD4 or NSC were analyzed
by immunoblot, left untreated or cisplatin-treated, and analyzed for
colony survival. Where shown, error bars represent the standard
deviation of the mean of three independent experiments.
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affected (Supplemental Fig. S4B,D,J). CHD4 depletion did
not enhance resistance of PEO1 cells to all drugs exam-
ined, including 6-thioguanine (6-TG) or melphalan
(Supplemental Fig. S3G,H). Thus, in response to diverse
DNA-damaging agents, CHD4 depletion improves fitness
in BRCA2 mutant, but not BRCA2-proficient, cells.
To test the possibility that CHD4 depletion uniquely
enhances cisplatin resistance when DNA repair is de-
fective, we analyzed other HR-defective cell lines. In the
BRCA1 mutant HCC1937 breast cancer cell line, CHD4
depletion greatly enhanced g-H2AX foci (Supplemental Fig.
S4E). Examination of either the HCC1937 or the BRCA1
mutant SUM1315MO2 breast cancer cell line revealed that
CHD4 depletion dramatically reduced proliferation such
that cisplatin toxicity could not be evaluated (Supplemen-
tal Fig. S5A–D).Moreover, CHD4-depleted PEO1 cellswere
resensitized to cisplatin upon BRCA1 depletion (Supple-
mental Fig. S5E,F). In DNA repair-defective cell lines,
including FANCJ mutant (FA-J) cells, FANCD2 mutant
(PD20) cells, or XPF mutant (XP-F) cells, CHD4 depletion
did not affect proliferation, and cisplatin resistance was not
enhanced (Supplemental Fig. S5G–L). Taken together,
CHD4 depletion mediates resistance to cisplatin specifi-
cally in a BRCA2 mutant background.
Due to HR defects, BRCA2 mutant cells display
chromosomal aberrations following cisplatin treatment.
The average number of radials induced by cisplatin per
metaphase spread in PEO1 cells significantly decreased
following CHD4 depletion and was comparable with that
in C4-2 cells (Fig. 2B,C), suggesting that HR was restored.
However, depletion of CHD4 in PEO1 cells did not in-
crease RAD51 foci formation or its nuclear localization
(Fig. 3A–C; Supplemental Fig. S6A). We also found that
CHD4 depletion did not change the expression and size of
BRCA2 in PEO1 cells (Fig. 3C). Consistent with the
conclusion that HR is not restored, CHD4 depletion did
not enhance break-induced HR in the BRCA2 mutant
VC-8 hamster cell line that includes an integrated SCE-1
break-inducible DR-GFP reporter, (Pierce et al. 1999),
but GFP-positive cells were recovered, as expected, by
introduction of a functional BRCA2 (Fig. 3D; Siaud et al.
2011).
Cisplatin resistance can also result from DNA damage
tolerance mechanisms that include error-prone trans-
lesion synthesis (TLS) polymerases that bypass DNA
lesions (Lehmann et al. 2007; Wang et al. 2009; Doles
et al. 2010; Xie et al. 2010). TLS is initiated by RAD6/
RAD18-dependent ubiquitination of the proliferating cell
nuclear antigen (PCNA) (Lehmann et al. 2007). Notably,
CHD4 depletion inBRCA2mutant PEO1 and FA-D1 cells
induced a modification on PCNA that increased its size
by ;8.5 kDa, and this modification was increased by
treatment with cisplatin. This modification was not
present in PEO1 cells expressing a control shRNA,
BRCA2-proficient C4-2 cells, or MBD2-depleted PEO1
cells (Fig. 4A–C; Supplemental Fig. S6D). The PCNA
modification also stained positively with antibodies to
ubiquitin, suggesting that the modification represents
a monoubiquitinated form of PCNA (Supplemental Fig.
S6B,C). Correspondingly, CHD4 depletion significantly
increased the average number of PEO1 cells with RAD18
foci (Fig. 4D,E).
We also examined whether CHD4 depletion enhanced
TLS by measuring the induction of inactivating muta-
tions at the endogenous hypoxanthine phosphoribosyl-
transferase (HPRT) locus (Fig. 4F; Chiu et al. 2006).
Suggesting induction of a mutagenic pathway, CHD4
depletion increased the mutation frequency in both un-
treated and cisplatin-treated PEO1 cells as comparedwith
PEO1 or C4-2 cells expressing control shRNAs, as evi-
denced by enhanced colony formation in 6-TG (Fig. 4G).
We next sought to determine whether a RAD18-depen-
dent pathway was required for cisplatin resistance. Com-
pared with CHD4 depletion alone, colony formation after
treatment with cisplatin was significantly reduced by
codepletion of CHD4 and RAD18 (Fig. 4H,I). These
findings suggest that in BRCA2 mutant cells, CHD4
depletion primes a RAD18-dependent mechanism that
confers cisplatin resistance.
Finally, we evaluated the clinical relevance of our results.
First, we examined and validated a series of previously
derived PEO1 clones that lack BRCA2 reversionmutations
and RAD51 foci formation but were cisplatin-resistant by
an unknown mechanism (Fig. 5A–C; Sakai et al. 2009).
Remarkably, in cisplatin-resistant clones C4-4, C4-11, and
C4-13, CHD4 protein levels are reduced as compared with
parental PEO1 cells or the BRCA2 revertant C4-2 (Fig. 5D).
Moreover, ectopic expression of CHD4 increased apoptosis
more dramatically in clones C4-4, C4-11, andC4-13 than in
PEO1 cells (Fig. 5E,F). Suggesting that resistant clones with
reduced CHD4 expression operate similarly to CHD4-de-
pleted PEO1 cells that were reliant on DNA damage
tolerance, RAD18 depletion also reduced cisplatin resis-
tance in C4-4, C4-11, and C4-13 clones but not in PEO1 or
C4-2 cells (Fig. 5G,H).
We next asked whether there was a relationship between
CHD4 expression and the response of ovarian cancer
patients. CHD4 mRNA levels were analyzed in serous
ovarian cancers for which OS (n = 315) and PFS (n = 260)
were documented (The Cancer Genome Atlas Research
Figure 3. CHD4 depletion in BRCA2 mutant cells does not restore
HR. (A) Cells were left untreated or treated with cisplatin and
coimmunostained with the indicated antibodies. A representative image
of cisplatin-treated cells is shown. (B) Depletion of NSC verses CHD4
was confirmed by immunoblot with the indicated antibodies, and the
percentage of cells with RAD51 foci or gH2AX foci was quantified. (C)
Cells were left untreated or cisplatin-treated, and nuclear extracts were
analyzed with the indicated antibodies. (D) VC8 hamster cells were
analyzed as in B and quantified for the percentage of GFP-positive cells
by flow cytometry using the DR-GFP HR reporter assay.
Therapy resistance in BRCA2 cancer by CHD4 loss
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Network 2011; Cerami et al. 2012; Gao et al. 2013). Median
CHD4 expression was used as a threshold to classify
cancers as CHD4-overexpressed (above median) or CHD4-
underexpressed (below median), and PFS and OS were
assessed. In sporadic cancers, CHD4 expression levels
displayed no significant correlation with PFS or OS (Fig.
5I). Strikingly, analysis of CHD4 mRNA specifically in
BRCA2 mutant ovarian cancers revealed that low CHD4
expression significantly correlated with shorter PFS (n = 29)
and shorter OS (n = 32), (Fig. 5J). Low CHD4 expression also
correlated with shorter OS in 22 BRCA2 mutant breast
cancers (Supplemental Fig. S7A,B). These results suggest
that CHD4 mRNA expression levels could serve as a valu-
able predictor of response to chemotherapy in ovarian and
potentially other cancers carrying a BRCA2 mutation.
Here, through an unbiased RNAi screen, we identified
the NuRD protein CHD4 as a factor that modulates
response to cisplatin and other DNA-damaging agents
in BRCA2 mutant cells. Suggesting that CHD4 also
modulates chemotherapeutic responsiveness in the
clinic, reduced levels of CHD4 mRNA significantly
correlate with shorter PFS and OS in BRCA2 mutant
ovarian cancers. Loss of CHD4 expression promotes
resistance to cisplatin by a mechanism independent of
HR but dependent on RAD18 (see model, Fig. 5K). TLS
has been shown to mediate cisplatin resistance in cancer
models (Wang et al. 2009; Doles et al. 2010; Xie et al.
2010), but aside from monoubiquitination of PCNA,
limited biomarkers exist to determine whether TLS is
up-regulated. TLS activation could also be
a consequence of changes in chromatin
conformation, as CHD4 has a defined role
in nucleosome remodeling. Our study dem-
onstrates that CHD4 depletion enhances
PCNA monoubiquitination uniquely in
BRCA2 mutant cells. However, CHD4 de-
pletion also enhanced PCNA monoubiqui-
tination in cells depleted for ZBTB1, a zinc
finger transcription factor that promotes
RAD18 accessibility during chromatin
remodeling (Kim et al. 2014). Taken to-
gether, this suggests that CHD4 serves as
a negative regulator of PCNA monoubi-
quitination and TLS. Our study did not
reveal any correlation with CHD4 deple-
tion and restored cisplatin resistance in
BRCA1, FANCJ, FANCD2, or XPF mutant
cells. In these repair-compromised cells, it
remains to be determined whether PCNA
monoubiquitination and/or TLS activa-
tion or processing is dependent on CHD4.
Defining the genetic background for which
CHD4 depletion enables TLS will be an
important future direction to determine
whether CHD4 mediates chemotherapeu-
tic response beyond BRCA2 mutant ovar-
ian or breast cancers.
Materials and methods
Cell lines
Ovarian cancer cell lines PEO1, C4-4, C4-11, C4-13, and
C4-2 were grown in DMEM with 10% FBS and 1%
Glutmax, and VC8, FA-D1, XP-F, PD20, and FA-J cells
were grown in DMEMwith 15% FBS. We thank Toshi Taniguchi for PEO1
cells series, Orlando Scharer for XP-F cells, and Maria Jasin for VC8 cells.
Immunofluorescence
Cells grown on coverslips were fixed for 10minwith 3%paraformaldehyde/
2% sucrose in phosphate-buffered saline (PBS). For RAD18 foci, 3.7%
formaldehyde in PBS was used as fixative. Cells were then permeabilized
for 5minwith 0.5%Triton X-100 in PBS. Coverslipswere rinsed three times
in PBS prior to each step. For primary and secondary staining, cells were
incubated for 40 min each in a humid chamber, face down on a 100-mL
meniscus of antibodies diluted in 3% BSA in PBS. Primary antibodies used
were anti-RAD51 poly (1:500; Santa Cruz Biotechnology), anti-g H2AX
mono (1:500; Millipore), and anti-RAD18 mono (1:400; Abcam). Secondary
antibodies included Rhodamine Red-X-conjugated AffiniPure goat anti-
rabbit IgG and fluorescein (FITC)-conjugated AffiniPure goat anti-mouse
IgG (Jackson ImmunoResearch Laboratories. Inc.). Coverslips were mounted
on slides using VectaShield mounting medium with DAPI (Vector Labora-
tories, Inc.) and analyzed on a fluorescence microscope (Leica, DM 5500B)
with a Qimaging Retiga 2000R fast 1394 camera. For flow cytometry
experiments examining apoptosis, live cells were collected and stained using
the Annexin V-FITC and propidium iodide apoptosis detection kit (Abcam).
RNAi
The packaging cell line 293TL was used to produce lentiviral particles
containing pGIPZ or pLKO.1 vectors. Cells were transfected with 1:1:2 mg
of DNA packaging versus insert using Effectene transfection reagent
(Qiagen) 48 h prior to harvesting supernatants. Supernatants were filtered
and added to recipient cell lines with 1 mg/mL polybrene. Cells infected
with shRNA vectors were selected with puromycin (pGIPZ and pLKO.1).
For shRNA-mediated silencing, the mature sense was used for pGIPZ,
Figure 4. CHD4 depletion in BRCA2 mutant cells enhances DNA damage tolerance.
(A–C) BRCA2 mutant PEO1 cells (A), BRCA2 mutant FA-D1 cells (B), and BRCA2
revertant C4-2 cells (C) expressing pLKO.1 vectors targeting NSC or CHD4 were left
untreated or cisplatin-treated, and nuclear extracts were analyzed with the indicated
antibodies. Arrows indicate molecular weight of ;37 kDa. (D) Cells were left untreated
or cisplatin-treated and coimmunostained with the indicated antibodies. A representa-
tive image of cisplatin-treated cells is shown. (E) Quantification of the average fold
increase in cells with RAD18 foci. (F) Schematic of HPRT mutagenesis assay. (G)
Quantitation of HPRT mutagenesis assay. (H) PEO1 cells expressing pLKO.1 shRNAs
targeting NSC or CHD4 were codepleted of RAD18 with two unique vectors versus
NSC and analyzed by immunoblot blot with the indicated antibodies. (I) Cells were left
untreated or cisplatin-treated and quantified for colony survival. Where shown, error
bars represent the standard deviation of the mean of three independent experiments.
Guillemette et al.
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CHD4-1 (59-ATTCATAGGATGTCAGCAG-39) and CHD4-2 (59-TTAGT
TCTGTCTTGGAGGG-39); pLKO.1, CHD4-3 (59-GCTGCTGACATCC
TATGAATT-39) and CHD4-4 (59-GCTGACACAGTTATTATCTAT-39);
pLKO.1, CHD4-(UTR)39 (59-GCCTGTTACACACAAACTGT-39); pLKO.1,
CHD3-1 (59-CCTCCCACACTGCCAAGTATA-39); pLKO.1, CHD3-2 (59-
GCCATTATCAACGAGCCATTT-39); pLKO.1, MBD2-1 (59-GCCTAG
TAAATTACAGAAGAA-39) and MBD2-2 (59-GTACGCAAGAAATTG
GAAGAA-39); pGIPZ, RAD18-1 (59-TTTGGTCTTTGCAGCAGGGCTC-
39); and pLKO.1, RAD18-2 (59-CCCTCGACATCCACTTTGAAA-39).
shRNA screen
The human shRNAmir pGIPZ library (release 6, Open Biosystems) was
obtained through the University of Massachusetts Medical School RNAi
core facility. Lentiviral pools were generated and used to transduce PEO1
cells as described at a multiplicity of infection (MOI) of 0.2 (Gazin et al.
2007). Cells that bypassed two cycles of 2 mM cisplatin
treatment (enough to induce ;100% lethality in the
shNSC pool) underwent cellular proliferation to form
colonies. Colonies were pooled and expanded, and the
shRNAs were identified by sequence analysis as pre-
viously described (Gazin et al. 2007). Individual knock-
down cell lines were generated by stable transduction of
6 3 105 cells with a single shRNA.
Immunoblot
Cells were lysed in 150 mM NETN lysis buffer (20 mM
Tris at pH 8.0, 150mMNaCl, 1 mMEDTA, 0.5%NP-40,
1 mM phenylmethylsulfonyl fluoride, 13 protease in-
hibitor cocktail) for 30 min on ice. Cell extracts were
clarified by centrifugation at 14,000 rpm, protein was
quantified by Bradford assay, and lysates were boiled in
SDS loading buffer. Nuclear extracts were prepared with
a nuclear extraction kit (ThermoFisher) with 1 mM
phenylmethylsulfonyl fluoride, 13 protease inhibitor
cocktail, and 20 mM N-ethylmaleimide, and proteins
were separated by SDS-PAGE on 4%–12% bis Tris or
3%–8% Tris acetate gels (Novex, Life Technologies) and
electrotransferred onto nitrocellulose membranes.
Membranes were blocked in 5% milk diluted in PBS.
Antibodies used for immunoblot analysis included
anti-BRCA2 poly (1:1000; Abcam), anti-CHD4 mono
(1:1000; Abcam), anti-RAD51 poly (1:500; Santa Cruz
Biotechnology), anti-RAD51 mono (1:1000; Milli-
pore), anti-MCM7 mono (1:1000; Santa Cruz Biotech-
nology), anti-MBD2 mono (1:1000; Santa Cruz Biotech-
nology), anti-CHD3 mono (1:1000; Abcam), anti-g
H2AX mono (1:500; Millipore), anti-PCNA mono
(1:1000; Abcam), anti-ubiquitin mono (1:1000; Abcam),
anti-RAD18 mono (1:500; Abcam), anti-HA mono
(1:2000; Cell Signaling), anti-bACTIN (1:5000; Abcam),
and Caspase3 (1:1000; Cell Signaling). Membranes were
washed and incubated with horseradish peroxidase-
linked secondary antibodies (1:5000; Amersham) and
detected by chemiluminescence (Ambersham).
Metaphase spreads
Cells were treated with 0.25 mM cisplatin for 60 h and
incubated with 150 mL of 10 mg/mL colecemid (Life
Technologies) for 2–3 h, and medium and cells were
collected. Cells were lysed with 75 mM prewarmed KCl
(hypotonic buffer) in a 37°Cwater bath, and 100 mL of 3:1
methanol/acetic acid was added dropwise to stop the
reaction. Cells were then collected and resuspended in
3:1 methanol/acetic acid fixative solution for 20 min on
ice, which was repeated three times. Cells were dropped
from a bench top onto sides andmounted with VectaShield
mounting medium with DAPI (Vector Laboratories,
Inc.). Spreads were viewed under high magnification
with oil to observe radials.
Survival analysis
The serous ovarian cancer Affymetrix U133 raw gene expression data set
or breast cancer data set was retrieved from the Cancer Genome Atlas
(TCGA), and survival analysis was performed using BRB-ArrayTools
version 4.2 (Biometrics Research Branch, National Cancer Institute).
Median CHD4 mRNA expression was used as a threshold to classify
cancers as CHD4-overexpressed (above median) or CHD4-underexpressed
(below median).
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